Who we are

The Cancer Screening and Prevention Research Group (CSPRG) is an internationally renowned research group based at Imperial College London. Headed by Professor Wendy Atkin, the group has extensive expertise in conducting clinical trials and includes an experienced team of research scientists, statisticians, clinical trial managers, data analysts, data managers and science writers.

What we do

The research focus of the Cancer Screening and Prevention Research Group (CSPRG) is bowel cancer, also known as colorectal cancer. In the UK, over 41,000 people are diagnosed with bowel cancer every year and 16,000 people die from the disease. Through our research we hope to reduce the numbers of people receiving a diagnosis of bowel cancer and dying from this disease. Much of our work focuses on how to help make bowel cancer screening programmes more effective and acceptable for participants, and more efficient for the NHS, and other health services internationally.

How we do it

We conduct large scale studies by either recruiting people from participating healthcare providers or by collating and analysing data collected from UK based hospitals and other data providers.

How we are funded

We receive funding from the UK Government, through the Department of Health and research councils, as well as charities including Cancer Research UK and the Bobby Moore Fund. The Faecal Immunochemical Tests (FIT) for the FIT For Follow-Up study are provided in kind by Eiken Chemical Co. Ltd and Mast Group Ltd. KeyMed Ltd provided funding in 1994 for a pilot study in preparation for the UK Flexible Sigmoidoscopy Screening Trial (UKFSST).

Information we may hold about you and your options if you wish to opt-out.

If you have taken part in a cancer screening programme, gone to your GP with symptoms suggestive of colorectal cancer, agreed to participate in one of our studies or had cancer treatment on the NHS, we may retain some information about you. Our Patient Data page provides further details on how we process this data and and your options if you wish to opt-out.